[go: up one dir, main page]

SG11201700073PA - Methods for the treatment of hepatitis b and hepatitis d virus infections - Google Patents

Methods for the treatment of hepatitis b and hepatitis d virus infections

Info

Publication number
SG11201700073PA
SG11201700073PA SG11201700073PA SG11201700073PA SG11201700073PA SG 11201700073P A SG11201700073P A SG 11201700073PA SG 11201700073P A SG11201700073P A SG 11201700073PA SG 11201700073P A SG11201700073P A SG 11201700073PA SG 11201700073P A SG11201700073P A SG 11201700073PA
Authority
SG
Singapore
Prior art keywords
hepatitis
treatment
methods
virus infections
infections
Prior art date
Application number
SG11201700073PA
Inventor
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201700073P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of SG11201700073PA publication Critical patent/SG11201700073PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
SG11201700073PA 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections SG11201700073PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Publications (1)

Publication Number Publication Date
SG11201700073PA true SG11201700073PA (en) 2017-02-27

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700073PA SG11201700073PA (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Country Status (33)

Country Link
US (1) US9603865B2 (en)
EP (1) EP3166615B1 (en)
JP (2) JP2017521433A (en)
KR (2) KR20170029577A (en)
CN (2) CN113750112A (en)
AU (1) AU2015286199B2 (en)
BR (1) BR112017000320B1 (en)
CA (1) CA2954182C (en)
CL (1) CL2017000008A1 (en)
CU (1) CU20170001A7 (en)
DK (1) DK3166615T3 (en)
DO (1) DOP2017000002A (en)
EA (1) EA036745B1 (en)
EC (1) ECSP16097355A (en)
ES (1) ES2963814T3 (en)
FI (1) FI3166615T3 (en)
HK (1) HK1231402A1 (en)
HR (1) HRP20231400T1 (en)
HU (1) HUE064449T2 (en)
IL (1) IL249660B (en)
LT (1) LT3166615T (en)
MD (1) MD4760C8 (en)
MX (1) MX381042B (en)
MY (1) MY178087A (en)
PH (1) PH12017500010B1 (en)
PL (1) PL3166615T3 (en)
PT (1) PT3166615T (en)
RS (1) RS64833B1 (en)
SG (1) SG11201700073PA (en)
SI (1) SI3166615T1 (en)
SM (1) SMT202300380T1 (en)
TW (1) TWI766831B (en)
WO (1) WO2016004525A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53674A (en) * 2018-11-08 2021-07-28 Aligos Therapeutics Inc ANTIGEN TRANSPORT-INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN113637030A (en) * 2020-05-07 2021-11-12 西安新通药物研究股份有限公司 Paradofovir mesylate B crystal form and application thereof
WO2021223398A1 (en) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 Crystal form for treating liver disease and use thereof
CN114057816B (en) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 Adenine-rich phosphorothioate oligonucleotides and their application in anti-hepatitis virus
US20220160748A1 (en) * 2020-11-20 2022-05-26 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (en) 2020-12-18 2022-12-01 美商詹森藥物公司 Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
CA3224600A1 (en) 2021-07-09 2023-01-12 Glaxosmithkline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
CA2498777C (en) 2002-09-13 2015-01-13 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2006091798A2 (en) * 2005-02-22 2006-08-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus
CA2855690C (en) 2010-08-20 2015-08-25 Replicor Inc. Oligonucleotide chelate complexes
EP2632472B1 (en) * 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
CA2873529C (en) * 2012-05-18 2020-08-18 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
AR091065A1 (en) * 2012-05-18 2014-12-30 Replicor Inc A PHARMACEUTICAL FORMULATION THAT INCLUDES AN ANTIVIRAL OLIGONUCLEOTIDE CHELATE FOR THE TREATMENT OF AN ANTI-VIRAL INFECTION
WO2014032176A1 (en) * 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
RS64833B1 (en) 2023-12-29
MY178087A (en) 2020-10-02
AU2015286199B2 (en) 2020-05-14
AU2015286199A1 (en) 2017-02-23
ES2963814T3 (en) 2024-04-02
FI3166615T3 (en) 2023-11-06
US20160008393A1 (en) 2016-01-14
TW201613617A (en) 2016-04-16
EA201790160A1 (en) 2017-06-30
MX381042B (en) 2025-03-12
MX2017000053A (en) 2017-05-01
CN113750112A (en) 2021-12-07
US9603865B2 (en) 2017-03-28
JP2017521433A (en) 2017-08-03
WO2016004525A1 (en) 2016-01-14
ECSP16097355A (en) 2017-03-31
NZ727583A (en) 2024-08-30
KR20170029577A (en) 2017-03-15
BR112017000320B1 (en) 2023-02-07
PH12017500010A1 (en) 2017-05-15
JP2020143065A (en) 2020-09-10
EP3166615B1 (en) 2023-08-09
SI3166615T1 (en) 2023-12-29
HRP20231400T1 (en) 2024-02-16
LT3166615T (en) 2024-01-25
MD20170014A2 (en) 2017-07-31
SMT202300380T1 (en) 2024-01-10
MD4760C8 (en) 2022-02-28
MD4760B1 (en) 2021-07-31
DK3166615T3 (en) 2023-11-13
EP3166615A4 (en) 2018-01-17
DOP2017000002A (en) 2017-03-15
CA2954182A1 (en) 2016-01-14
IL249660A0 (en) 2017-02-28
KR102734495B1 (en) 2024-11-25
PL3166615T3 (en) 2024-02-19
EP3166615A1 (en) 2017-05-17
EA036745B1 (en) 2020-12-16
CU20170001A7 (en) 2017-04-05
CL2017000008A1 (en) 2017-06-09
IL249660B (en) 2022-02-01
BR112017000320A2 (en) 2017-11-07
PT3166615T (en) 2023-11-13
CN106659730A (en) 2017-05-10
TWI766831B (en) 2022-06-11
PH12017500010B1 (en) 2022-07-29
KR20230070330A (en) 2023-05-22
JP6922030B2 (en) 2021-08-18
CA2954182C (en) 2023-08-15
HUE064449T2 (en) 2024-03-28
HK1231402A1 (en) 2017-12-22

Similar Documents

Publication Publication Date Title
ZA201903906B (en) Phosphoramidates for the treatment of hepatitis b virus
IL272820A (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL245436A0 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
IL246449B (en) 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP3240787A4 (en) Derivatives and methods of treating hepatitis b infections
EP3139954A4 (en) Methods and compositions for treating hepatitis b virus infections
SG11201605649TA (en) Azepane derivatives and methods of treating hepatitis b infections
IL251707A0 (en) Methods for treating filoviridae virus infections
IL249660A0 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
IL273932A (en) Viral treatment and prophylaxis methods
LT3137078T (en) Treatment of hepatitis delta virus infection
EP3226973A4 (en) Treatment of hepatitis delta virus infection
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
TH1601001266A (en) Methods and pharmaceutical compositions for the treatment of hepatitis B infection.
HK1225028A1 (en) Azepane derivatives and methods of treating hepatitis b infections
AU2014900488A0 (en) Agents and methods for inhibiting virus infection